

05/23/00
Jc6820 U.S. PTO

05-24-00

Box/SEQ

A

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Jc6640 U.S. PTO
09/576778
05/23/00

Re: U.S. Patent Application for
Title: Family 9 Endo-Beta-1,4-Glucanases
Applicants: Schülein et al.

Sir:

Express Mail Label No. EL 636738695US

Date of Deposit : May 23, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Sequence Amendment
6. Sequence Listing
7. Disk containing sequence listing

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Carol McFarlane

(Name of person mailing paper(s) or fee)

[Signature]

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL 636738695US

Date of Deposit May 23, 2000

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of
Applicant(s): Schülein et al.

Title: Family 9 Endo-Beta-1,4-Glucanases

41 pages of specification 1 page of abstract

4 pages of sequence listing

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: 26 - 20 = 6 x 18 =	\$108.00
Independent Claims: 5 - 3 = 2 x 78 =	\$156.00
Total Fee:	\$954.00

Priority of Danish application no. PA 1999 00755 filed on May 28, 1999 is claimed under 35 U.S.C. 119. A certified copy will be submitted at a later date.

Priority of U.S. provisional application no. 60/137,295 filed on June 3, 1999 is claimed under 35 U.S.C. 119.


Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$954, to Novo Nordisk of North

America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 23, 2000



Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc.

405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123